Fludarabine
T-cell Leukemia
Xinqiao Hospital of ChongqingSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the T-cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE Children's Oncology Group | Phase 2 | B |
(+)-VINCRISTINE Children's Oncology Group | Phase 2 | B |
Cyclophosphamide Xinqiao Hospital of Chongqing | Phase 2 | B |
PEGASPARGASE Children's Oncology Group | Phase 2 | B |
Cytosin-Arabinosid Children's Oncology Group | Phase 2 | B |
View all 29 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →